Kura Oncology (KURA) Stock Forecast, Price Target & Predictions
KURA Stock Forecast
Kura Oncology stock forecast is as follows: an average price target of $28.67 (represents a 37.31% upside from KURA’s last price of $20.88) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
KURA Price Target
The average price target for Kura Oncology (KURA) is $28.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $26.00. This represents a potential 37.31% upside from KURA's last price of $20.88.
KURA Analyst Ratings
According to 3 Wall Street analysts, Kura Oncology's rating consensus is 'Buy'. The analyst rating breakdown for KURA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kura Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | Joseph Pantginis | H.C. Wainwright | $32.00 | $21.08 | 51.80% | 53.26% |
| May 23, 2024 | Bradley Canino | Stifel Nicolaus | $28.00 | $21.43 | 30.66% | 34.10% |
| Dec 22, 2023 | Mara Goldstein | Mizuho Securities | $26.00 | $13.81 | 88.27% | 24.52% |
The latest Kura Oncology stock forecast, released on Jun 25, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $32.00, which represents a 51.80% increase from the stock price at the time of the forecast ($21.08), and a 53.26% increase from KURA last price ($20.88).
Kura Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $32.00 | $28.67 |
| Last Closing Price | $20.88 | $20.88 | $20.88 |
| Upside/Downside | -100.00% | 53.26% | 37.31% |
In the current month, the average price target of Kura Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kura Oncology's last price of $20.88. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 25, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Feb 25, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Kura Oncology's last stock rating was published by H.C. Wainwright on Jun 25, 2024. The company gave KURA a "Buy" rating, the same as its previous rate.
Kura Oncology Financial Forecast
Kura Oncology Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.27M | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $1.27M | $65.00K |
| High Forecast | - | - | - | - | - | - | - | - | $1.27M | $78.00K |
| Low Forecast | - | - | - | - | - | - | - | - | $1.27M | $52.00K |
| # Analysts | - | - | - | - | - | - | - | 10 | 13 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | - |
Kura Oncology's average Quarter revenue forecast for Mar 24 based on 10 analysts is -, with a low forecast of -, and a high forecast of -. KURA's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $1.27M (Dec 23).
Kura Oncology EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 13 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | $-46.55M | $-14.47M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $-15.27M |
| High Forecast | - | - | - | - | - | - | - | - | - | $-12.22M |
| Low Forecast | - | - | - | - | - | - | - | - | - | $-18.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.95% |
undefined analysts predict KURA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kura Oncology's previous annual EBITDA (undefined) of $NaN.
Kura Oncology Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 13 | 15 |
| Net Income | - | - | - | - | - | - | - | - | $-42.79M | $-14.74M |
| Avg Forecast | $-61.73M | $-60.21M | $-57.83M | $-55.23M | $-55.16M | $-54.18M | $-54.24M | $-45.91M | $-42.59M | $-14.74M |
| High Forecast | $-61.73M | $-60.21M | $-57.83M | $-55.23M | $-55.16M | $-51.60M | $-54.24M | $-45.91M | $-37.27M | $-11.79M |
| Low Forecast | $-61.73M | $-60.21M | $-57.83M | $-55.23M | $-55.16M | $-57.62M | $-54.24M | $-45.91M | $-51.72M | $-17.69M |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.00% |
Kura Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KURA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kura Oncology SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 13 | 15 |
| SG&A | - | - | - | - | - | - | - | - | $14.02M | $3.80M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Kura Oncology's average Quarter SG&A projection for Mar 24 is -, based on 10 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to KURA last annual SG&A of $14.02M (Dec 23).
Kura Oncology EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 13 | 15 |
| EPS | - | - | - | - | - | - | - | - | $-0.55 | $-0.45 |
| Avg Forecast | $-0.71 | $-0.69 | $-0.67 | $-0.64 | $-0.64 | $-0.63 | $-0.63 | $-0.55 | $-0.55 | $-0.45 |
| High Forecast | $-0.71 | $-0.69 | $-0.67 | $-0.64 | $-0.64 | $-0.60 | $-0.63 | $-0.55 | $-0.48 | $-0.36 |
| Low Forecast | $-0.71 | $-0.69 | $-0.67 | $-0.64 | $-0.64 | $-0.67 | $-0.63 | $-0.55 | $-0.67 | $-0.54 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.00% |
According to undefined Wall Street analysts, Kura Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KURA previous annual EPS of $NaN (undefined).
Kura Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals | $3.24 | $21.86 | 574.69% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| KALV | KalVista Pharmaceuticals | $11.14 | $26.00 | 133.39% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| COGT | Cogent Biosciences | $10.63 | $18.50 | 74.04% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $25.26 | $37.00 | 46.48% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
KURA Forecast FAQ
Is Kura Oncology a good buy?
Yes, according to 3 Wall Street analysts, Kura Oncology (KURA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of KURA's total ratings.
What is KURA's price target?
Kura Oncology (KURA) average price target is $28.67 with a range of $26 to $32, implying a 37.31% from its last price of $20.88. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kura Oncology stock go up soon?
According to Wall Street analysts' prediction for KURA stock, the company can go up by 37.31% (from the last price of $20.88 to the average price target of $28.67), up by 53.26% based on the highest stock price target, and up by 24.52% based on the lowest stock price target.
Can Kura Oncology stock reach $30?
KURA's highest twelve months analyst stock price target of $32 supports the claim that Kura Oncology can reach $30 in the near future.
What are Kura Oncology's analysts' financial forecasts?
Kura Oncology's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-209M (high $-207M, low $-213M), average SG&A $0 (high $0, low $0), and average EPS is $-2.435 (high $-2.406, low $-2.475). KURA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-235M (high $-235M, low $-235M), average SG&A $0 (high $0, low $0), and average EPS is $-2.713 (high $-2.713, low $-2.713).
Did the KURA's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Dec 2023), Kura Oncology's revenue was $1.27M, beating the average analysts' forecast of $1.27M by 0%. The company's EBITDA was $-46.548M, beating the average prediction of $0 by 0%. Kura Oncology's net income was $-42.786M, beating the average estimation of $-42.595M by 0.45%. The company's SG&A was $14.02M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-0.551 by -0.14%